Iannaccone Teresa, Sellitto Carmine, Manzo Valentina, Colucci Francesca, Giudice Valentina, Stefanelli Berenice, Iuliano Antonio, Corrivetti Giulio, Filippelli Amelia
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
Clinical Pharmacology and Pharmacogenetics Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.
Pharmaceuticals (Basel). 2021 Mar 1;14(3):204. doi: 10.3390/ph14030204.
Pharmacogenomics can identify polymorphisms in genes involved in drug pharmacokinetics and pharmacodynamics determining differences in efficacy and safety and causing inter-individual variability in drug response. Therefore, pharmacogenomics can help clinicians in optimizing therapy based on patient's genotype, also in psychiatric and neurological settings. However, pharmacogenetic screenings for psychotropic drugs are not routinely employed in diagnosis and monitoring of patients treated with mood stabilizers, such as carbamazepine and valproate, because their benefit in clinical practice is still controversial. In this review, we summarize the current knowledge on pharmacogenetic biomarkers of these anticonvulsant drugs.
药物基因组学能够识别参与药物药代动力学和药效学过程的基因中的多态性，这些多态性决定了药物疗效和安全性的差异，并导致个体间药物反应的变异性。因此，药物基因组学有助于临床医生根据患者的基因型优化治疗方案，在精神科和神经科领域亦是如此。然而，对于使用心境稳定剂（如卡马西平和丙戊酸盐）治疗的患者，在诊断和监测过程中并未常规进行精神药物的药物遗传学筛查，因为其在临床实践中的益处仍存在争议。在本综述中，我们总结了关于这些抗惊厥药物的药物遗传学生物标志物的现有知识。
